Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
作者： Zhenfeng Zhang , Jae Cheol Lee , Luping Lin , Victor Olivas , Valerie Au
DOI: 10.1038/NG.2330
关键词: Cancer research 、 Tyrosine kinase 、 AXL receptor tyrosine kinase 、 Erlotinib Hydrochloride 、 Lung cancer 、 Biology 、 T790M 、 GAS6 、 Erlotinib 、 Targeted therapy
摘要: Human non–small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, …
core.ac.uk
elsevier.com
scienceopen.com
nature.com
sci-hub.se 参考文章(29)
Norio Azumi, Hector Battifora, The Distribution of Vimentin and Keratin in Epithelial and Nonepithelial Neoplasms: A Comprehensive Immunohistochemical Formalin- and Alcohol-Fixed Tumors American Journal of Clinical Pathology. ,vol. 88, pp. 286- 296 ,(1987) , 10.1093/AJCP/88.3.286
Rachel MA Linger, Amy K Keating, H Shelton Earp, Douglas K Graham, Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors Expert Opinion on Therapeutic Targets. ,vol. 14, pp. 1073- 1090 ,(2010) , 10.1517/14728222.2010.515980
Adi F. Gazdar, Personalized Medicine and Inhibition ofEGFRSignaling in Lung Cancer New England Journal of Medicine. ,vol. 361, pp. 1018- 1020 ,(2009) , 10.1056/NEJME0905763
Marie Brevet, Maria Arcila, Marc Ladanyi, Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR The Journal of Molecular Diagnostics. ,vol. 12, pp. 169- 176 ,(2010) , 10.2353/JMOLDX.2010.090140
KY Tai, YS Shieh, CS Lee, SG Shiah, Cheng-Wen Wu, None, Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1 Oncogene. ,vol. 27, pp. 4044- 4055 ,(2008) , 10.1038/ONC.2008.57
L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Science Translational Medicine. ,vol. 3, ,(2011) , 10.1126/SCITRANSLMED.3002003
K Vuoriluoto, H Haugen, S Kiviluoto, J-P Mpindi, J Nevo, C Gjerdrum, C Tiron, J B Lorens, J Ivaska, Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer Oncogene. ,vol. 30, pp. 1436- 1448 ,(2011) , 10.1038/ONC.2010.509
Alexa B. Turke, Kreshnik Zejnullahu, Yi-Long Wu, Youngchul Song, Dora Dias-Santagata, Eugene Lifshits, Luca Toschi, Andrew Rogers, Tony Mok, Lecia Sequist, Neal I. Lindeman, Carly Murphy, Sara Akhavanfard, Beow Y. Yeap, Yun Xiao, Marzia Capelletti, A. John Iafrate, Charles Lee, James G. Christensen, Jeffrey A. Engelman, Pasi A. Jänne, Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC Cancer Cell. ,vol. 17, pp. 77- 88 ,(2010) , 10.1016/J.CCR.2009.11.022
X Ye, Y Li, S Stawicki, S Couto, J Eastham-Anderson, D Kallop, R Weimer, Y Wu, L Pei, An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies Oncogene. ,vol. 29, pp. 5254- 5264 ,(2010) , 10.1038/ONC.2010.268
J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Janne, MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science. ,vol. 316, pp. 1039- 1043 ,(2007) , 10.1126/SCIENCE.1141478